Abstract 12095: Higher Salivary Cortisol Level Contributes to Exercise Intolerance via Reduced Muscle Strength in Patients With Chronic Heart Failure
Background: Chronic mental or physical stress increases cortisol secretion resulting in the elevation of cardiovascular risk. Some studies have documented that higher serum cortisol level indicates poor prognosis in patients with chronic heart failure (CHF). Although previous studies noted that cortisol reduced skeletal muscle mass as a catabolic action, the relationship between cortisol and physical function has not been thoroughly evaluated in them. We investigated whether higher salivary cortisol level contributes to exercise intolerance via reduced muscle strength in CHF patients.
Methods: We studied 70 patients with compensated CHF (63.9 ± 14.1 years, 56 males) who underwent cardiac rehabilitation during the hospitalization. The patients who had received major surgery within the past 6 months or had mental disorder were excluded from this study. We measured body mass index (BMI), left ventricular ejection fraction (LVEF), blood levels of albumin, C-reactive protein (CRP) and brain natriuretic peptide (BNP), muscle strength of grip and quadriceps, and peak oxygen consumption (VO2) obtained from cardiopulmonary exercise testing as exercise tolerance at hospital discharge. Saliva was collected after 20-minute rest, and salivary cortisol level was measured using ELISA method. Spearman’s rank correlation coefficient was used to assess the relationships between salivary cortisol level and parameters of clinical characteristics.
Results: Mean level of salivary cortisol was 1.9 ± 0.7 ng/mL in the present study. Figure 1 shows significant correlations of salivary cortisol level with quadriceps strength and peak VO2. Salivary cortisol level was also correlated with BNP (r = 0.40, p < 0.05) and grip strength (r = -0.53, p < 0.01). There were no significant correlations of salivary cortisol level with BMI, LVEF, albumin and CRP.
Conclusion: Higher salivary cortisol level contributed to exercise intolerance via reduced muscle strength in CHF patients.
Author Disclosures: N. Hamazaki: None. T. Masuda: None. K. Kamiya: None. R. Matsuzawa: None. K. Nozaki: None. S. Tanaka: None. R. Shimizu: None. A. Akiyama: None. D. Kamekawa: None. Y. Kamada: None. A. Aoyama: None. E. Maekawa: None. J. Ako: None.
- © 2014 by American Heart Association, Inc.